We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Laboratory Model Reveals Genetic Risk Loci for AMD

By LabMedica International staff writers
Posted on 20 May 2019
Eye disease researchers used advanced stem cell technology to create a laboratory model of age-related macular degeneration (AMD), which enabled in-depth analysis of the genetics underlying the syndrome.

AMD, one of the most common causes of vision loss in the elderly, causes the slow degradation of the cells comprising the macula of the retina, which is the region in the back of the eye that transmits information to the brain. More...
The exact cause of the disease is unknown, but studies have suggested that genetics plays an important role.

To define the role of genetic risk in AMD, investigators at the University of California, San Diego (USA) created an in vitro model based on human induced pluripotent stem cell-derived retinal pigment epithelium (iPSC-RPE) cells from six subjects. To do this, they generated iPSCs from skin cells, and then used a cocktail of molecules and growth factors to transform the iPSCs into retinal cells. The induced RPEs were found to have morphological and molecular characteristics similar to those of native RPE.

The model system was used to generate molecular data, including RNA transcripts and epigenetic information. These findings were combined with complementary published data from 18 adults with and without AMD.

Results revealed that the genetic variant most closely associated with AMD was rs943080, a specific genetic variation that affected expression of the VEGFA (vascular endothelial growth factor A) gene, possibly through regulation by a non-coding region of the genome. Five of the six participants had one copy of rs943080 and one person had two copies of the gene variant. VEGFA protein is known for supporting new blood vessel growth, a process that characterizes AMD.

"We did not start with the VEGFA gene when we went looking for genetic causes of AMD," said senior author Dr. Kelly A. Frazer, professor of pediatrics at the University of California, San Diego. "But we were surprised to find that, with samples from just six people, this genetic variation clearly emerged as a causal factor."

The authors concluded that their results had established a molecular hypothesis for the VEGFA genetic risk locus in AMD and illustrated the potential of iPSC-RPE as a model system to study the molecular function of genetic variation associated with AMD.

The AMD stem cell study was published in the May 9, 2019, online edition of the journal Stem Cell Reports.

Related Links:
University of California, San Diego


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The assay evaluates tumor-derived total nucleic acid extracted from CSF and detects multiple biomarker classes (Photo courtesy of Shutterstock)

New CSF Liquid Biopsy Assay Reveals Genomic Insights for CNS Tumors

Central nervous system (CNS) malignancies pose distinctive diagnostic challenges because tissue-based testing is often infeasible and the blood–brain barrier limits the usefulness of plasma liquid biopsy.... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Pathology

view channel
Image: Sophie Paczesny, M.D., Ph.D and her team have made BIOPREVENT freely available for researchers and clinician to test and learn from (Photo courtesy of Cliff Rhodes)

AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear

Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read more

Industry

view channel
Image

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.